Patients receiving post-transplant cyclophosphamide to prevent graft-versus-host disease have lower risk for bronchiolitis obliterans syndrome.

Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has assigned a ...

After over a decade with HIV, a Norwegian man received a surprise through a stem cell donation from his sibling. The gifted ...

A man with HIV entered long-term remission after receiving HIV-resistant stem cells through a bone marrow transplant to treat ...

The treatment for primary immunodeficient diseases is varied. As mentioned before, the most common type of primary immunodeficient disease are antibody deficiencies. Either patients don't make enough ...

Allogene Therapeutics (NASDAQ:ALLO) detailed interim results from its pivotal Phase II ALPHA3 study during a business update ...

Allogene jumps as cema-cel shows strong MRD clearance and safety in the ALPHA3 study, signaling potential in first-line LBCL ...

The American Association for Dental, Oral, and Craniofacial Research (AADOCR) has announced Jacqueline Mays as the 2026 inaugural recipient of the AADOCR SCADA/Dentsply Sirona Research Award.

Detailed price information for Mesoblast Ltd Ord (MEOBF) from The Globe and Mail including charting and trades.

Working with Parent Project Muscular Dystrophy and the Duchenne Registry on patient identification and trial awareness efforts ~15,000 children ...

The Health Insurance Fund (Tervisekassa) expanded its list of reimbursable medicines at the start of the month.

Mesoblast offers asymmetric risk-reward with Ryoncil's rapid pediatric SR-aGvHD launch and multiple late-stage pipeline catalysts. Learn why MESO stock is a hold.